Copper hypothesis in the missing hereditability of sporadic alzheimer's disease: ATP7B gene as potential harbor of rare variants

Journal of Alzheimer's Disease

Volumn 29, Issue 3, 2012, Pages 493-501

  Squitti, Rosanna ^a,b   Polimanti, Renato ^c  

^a IRCCS ISTITUTO CENTRO SAN GIOVANNI DI DIO FATEBENEFRATELLI   (Italy)

^b UNIVERSITY CAMPUS BIO MEDICO   (Italy)

^c UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

Alzheimer's disease; copper; genetic loci; genetic predisposition to disease

Indexed keywords

ADENOSINE TRIPHOSPHATASE; ADENOSINE TRIPHOSPHATE; AMYLOID BETA PROTEIN; APOLIPOPROTEIN E; CHELATING AGENT; COPPER; GAMMA SECRETASE INHIBITOR;

AGED; AGING; ALZHEIMER DISEASE; ARTICLE; ATP7B GENE; COPPER BLOOD LEVEL; DISEASE COURSE; DRUG EFFICACY; EARLY DIAGNOSIS; GENE; GENE LOCUS; GENE MUTATION; GENETIC ASSOCIATION; GENETIC PREDISPOSITION; GENOME; GENOTYPE PHENOTYPE CORRELATION; HERITABILITY; HUMAN; HYPOTHESIS; IMMUNIZATION; LATE ONSET ALZHEIMER DISEASE; LIVER CELL; METAL BINDING; ONSET AGE; OXIDATIVE STRESS; PRIORITY JOURNAL; SCREENING TEST; SENILE PLAQUE; WILSON DISEASE;

EID: 84859395496     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-2011-111991     Document Type: Article

References (48)

1. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM (1984) Clinical diagnosisof Alzheimer's disease: Report of the NINCDS-ADRDA Work Group under the auspices of department of health and human services task force on Alzheimer's disease. Neurology 34, 939-944. (Pubitemid 14076461)
2. Dubois B, Feldman C, Jacova C, Dekosky ST, Barberger-Gateau P, Cummings J, Delacourte A, Galasko D, Gauthier S, Jicha G, Meguro K, O'brienJ, Pasquier F, Robert P, Rossor M, Salloway S, Stern Y, Visser PJ, Scheltens P (2007) Research criteria for the diagnosis of Alzheimer's disease: Revising the NINCDSADRDA criteria. Lancet Neurol 6, 734-746. (Pubitemid 47058377)
3. Lopez OL, Swihart AA, Becker JT, Reinmuth OM, Reynolds CF 3rd, Rezek DL, Daly FL 3rd (1990) Reliability of NINCDS-ADRDA clinical criteria for the diagnosis of Alzheimer's disease. Neurology 40, 1517-1522. (Pubitemid 20351342)
4. Schofield PW, Tang M, Marder K, Bell K, Dooneief G, Lan-tigua R, Wilder D, Gurland B, Stern Y, Mayeux R (1995) Consistencyofclinicaldiagnosisinacommunity-based longitudinal study of dementia and Alzheimer's disease. Neurology 45, 2159-2164. (Pubitemid 27100240)
5. Querfurth HW, Laferla FM (2010) Alzheimer's disease. N Engl J Med 362, 329-344.
6. Bertram L, Lill CM, Tanzi RE (2010) The genetics of Alzheimer disease: Back to the future. Neuron 68, 270-281.
7. Luo L, Boerwinkle E, Xiong M (2011) Association studies for next-generation sequencing. Genome Res 21, 1099-1108.
8. De La Vega FM, Bustamante CD, Leal SM (2011) Genome-wide association mapping and rare alleles: From population genomics to personalized medicine-Session Introduction. Pac Symp Biocomput 2011, 74-75.
9. Barnham KJ, Haeffner F, Ciccotosto GD, Curtain CC, Tew D, Mavros C, Beyreuther K, Carrington D, Masters CL, Cherny RA, Cappai R, Bush AI (2004) Tyrosine gated electron transfer is key to the toxic mechanism of Alzheimer's disease beta-amyloid. FASEB J18, 1427-1429. (Pubitemid 39561603)
10. Atwood CS, Perry G, Zeng H, Kato Y, Jones WD, Ling KQ, Huang X, Moir RD, Wang D, Sayre LM, Smith MA, Chen SG, Bush AI (2004) Copper mediates dityrosine cross-linking of Alzheimer's amyloid-beta. Biochemistry 43, 560-568. (Pubitemid 38082580)
11. Kenche VB, Barnham KJ (2011) Alzheimer's disease & metals: Therapeutic opportunities. Br J Pharmacol 163, 211-219.
12. Bush AI, Tanzi RE (2008) Therapeutics for Alzheimer's disease based on the metal hypothesis. Neurotherapeutics 5, 421-432. (Pubitemid 351952485)
13. Multhaup G (1996) Alzheimer's precursor protein and the use of bathocuproine for determining reduction of copper (II). Scienc 274, 1934.
14. White AR, Multhaup G, Maher F, Bellingham S, Camakaris J, Zheng H, Bush AI, Beyreuther K, Masters CL, Cappai R (1999) The Alzheimer's disease amyloid precursor protein modulates copper-induced toxicity and oxidative stress in primary neuronal cultures. J Neurosci 19, 9170-9179. (Pubitemid 30228069)
15. Cherny RA, Legg JT, McLean CA, Fairlie DP, Huang X, Atwood CS, Beyreuther K, Tanzi RE, Masters CL, Bush AI (1999) Aqueous dissolution of Alzheimer's disease Afj amyloid deposits by biometal depletion. J Biol Chem 274, 23223-23228.
16. Squitti Pasqualetti P, Dal Forno G, Moffa F, Cassetta E, Lupoi D, Vernieri F, Rossi L, Baldassini M, Rossini PM (2005) Excess of serum copper not related to ceruloplasmin in Alzheimer disease. Neurology 64, 1040-1046. (Pubitemid 40388458)
17. Squitti R, Barbati G, Rossi L, Ventriglia M, Dal Forno G, Cesaretti S, Moffa F, Caridi I, Cassetta E, Pasqualetti P, Calabrese L, Lupoi D, Rossini PM (2006) Excess of non-ceruloplasmin serum copper in AD correlates with MMSE, CSF fj-amyloid, and h-tau. Neurology 67, 76-82. (Pubitemid 44305465)
18. Squitti R, Bressi P, Pasqualetti P, Bonomini C, Ghidoni R, Binetti G, Cassetta E, Moffa F, Ventriglia M, Vernieri F, Rossini PM (2009) Longitudinal prognostic value of serum "free" copper in patients with Alzheimer disease. Neurology 72, 50-55.
19. Lam PK, Kritz-Silverstein D, Barrett Connor E, Milne D, Nielsen F, Gamst A, Morton D, Wingard D (2008) Plasma trace elements and cognitive function in older men and women: The Rancho Bernardo study. J Nutr Health Aging 12, 22-27. (Pubitemid 351156011)
20. Loef M, Walach H (2011) Copper and iron in Alzheimer's disease: A systematic review and its dietary implications. Br J Nutr, doi: 10.1017/S000711451100376X.
21. Schrag M, Mueller C, Oyoyo U, Smith MA, Kirsch WM (2011) Iron, zinc and copper in the Alzheimer's disease brain: A quantitative meta-analysis. Some insight on the influence of citation bias on scientific opinion. Prog Neurobiol 94, 296-306.
22. Bucossi S, Ventriglia M, Panetta V, Salustri C, Pasqualetti P, Mariani S, Siotto M, Rossini PM, Squitti R (2011) Copper in Alzheimer's disease: A meta-analysis of serum, plasma, and cerebrospinal fluid studies. J Alzheimers Dis 24, 175-185.
23. Squitti R, Rossini PM, Cassetta E, Moffa F, Pasqualetti P, Cortesi M, Colloca A, Rossi L, Finazzi-Agro A (2002) d-penicillamine reduces serum oxidative stressinAlzheimer's disease patients. Eur J Clin Invest 32, 51-59. (Pubitemid 36228383)
24. Ritchie CW, Bush AI, Mackinnon A, Macfarlane S, Mastwyk M, MacGregor L, Kiers L, Cherny R, Li QX, Tammer A, Carrington D, Mavros C, Volitakis I, Xilinas M, Ames D, Davis S, Beyreuther K, Tanzi RE, Masters CL (2003) Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Abeta amyloid deposition and toxicity in Alzheimer disease: A pilot phase 2 clinical trial. Arch Neurol 60, 1685-1691. (Pubitemid 37521621)
25. Lannfelt L, Blennow K, Zetterberg H, Batsman S, Ames D, Harrison J, Masters CL, Targum S, Bush AI, Murdoch R, Wilson J, Ritchie CW, PBT2-201-EURO study group (2008). Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer's disease: A phase IIa, double-blind, randomised, placebo-controlled trial. Lancet Neurol 7, 779-786.
26. Squitti R, Salustri C (2009) Agents complexing copper as a therapeutic strategy for the treatment of Alzheimer's disease. Curr Alzheimer Res 6, 476-487.
27. Arnal N, Cristalli DO, de Alaniz MJ, Marra CA (2010) Clinical utility of copper, ceruloplasmin, and metallothionein plasma determinations in human neurodegenerative patients and their first-degree relatives. Brain Res 1319, 118-130.
28. Squitti R, Ghidoni R, Scrascia F, Benussi L, Panetta V, Pasqualetti P, Moffa F, Bernardini S, Ventriglia M, Binetti G, Rossini PM (2011) Free copper distinguishes mild cognitive impairment subjects from healthy elderly individuals. J Alzheimers Dis 23, 239-248.
29. Walshe JM (2003) Wilson's disease: The importance of measuring serum caeruloplasmin non-immunologically. Ann Clin Biochem 40, 115-121. (Pubitemid 36359861)
30. Hartter DE, Barnea A (1988) Brain tissue accumulates copper by two ligand-dependent saturable processes. A high affinity, low capacity and a low affinity, high capacity process. J Biol Chem 263, 799-805. (Pubitemid 18044707)
31. Choi BS, Zheng W (2009) Copper transport tothe brain bythe blood-brain barrier and blood-CSF barrier. Brain Res 1248, 14-21.
32. Panagiotakaki E, Tzetis M, Manolaki N, Loudianos G, Pap-atheodorou A, Manesis E, Nousia-Arvanitakis S, Syriopoulou V, Kanavakis E (2004) Genotype-phenotype correlations for a wide spectrum of mutations in the Wilson disease gene (ATP7B). Am J Med Genet A 131, 168-173. (Pubitemid 39578349)
33. Ferenci P, Członkowska A, Merle U, Ferenc S, Gromadzka G, Yurdaydin C, Vogel W, Bruha R, Schmidt HT, Stremmel W (2007) Late-onset Wilson's disease. Gastroenterology 132, 1294-1298. (Pubitemid 46627596)
34. Reitz C, Mayeux R (2009) Use of genetic variation as biomarkers for Alzheimer's disease. Ann N Y Acad Sci 1180, 75-96.
35. Moore JH, Asselbergs FW, Williams SM (2010) Bioin-formatics challenges for genome-wide association studies. Bioinformatics 26, 445-455.
36. Stranger BE, Stahl EA, Raj T (2011) Progress and promise of genome-wide association studies for human complex trait genetics. Genetics 187, 367-383.
37. Torsdottir G, Kristinsson J, Snaedal J, Sveinbjörnsdóttir S, Gudmundsson G, Hreidarsson S, Jóhannesson T (2011) Case-control studies on ceruloplasmin and superoxide dismutase (SOD1) inneurodegenerative diseases: A short review. J Neu-rol Sci 299, 51-54.
38. Snaedel et al. (1998) Copper, ceruloplasmin and superoxide dismutase in patients with Alzheimer's disease: A case-control study. Dement Geriatr Cogn Disord 9, 239-242.
39. Brewer GJ, Kanzer SH, Zimmerman EA, Celmins DF, Heckman SM, Dick R (2010) Copper and ceruloplasmin abnormalities in Alzheimer's disease. Am J Alzheimers Dis Other Demen 25, 490-497.
40. Kessler H, Pajonk FG, Meisser P, Schneider-Axmann T, Hoffmann KH, Supprian T, Herrmann W, Obeid R, Multhaup G, Falkai P, Bayer TA (2006) Cerebrospinal fluid diagnostic markers correlate with lower plasma copper and ceruloplas-min in patients with Alzheimer's disease. J Neural Transm 113, 1763-1769. (Pubitemid 44657672)
41. Capo CR, Arciello M, Squitti R, Cassetta E, Rossini PM, Calabrese L, Rossi L (2008) Features of ceruloplasmin in the cerebrospinalfluid ofAlzheimer's disease patients. Biometals 21, 367-372.
42. Squitti R, Quattrocchi CC, Salustri C, Rossini PM (2008) Ceruloplasmin fragmentation is implicated in 'free' copper deregulation of Alzheimer's disease. Prion 2, 23-27.
43. Squitti R, Salustri C, Siotto M, Ventriglia M, Vernieri F, Lupoi D, Cassetta E, Rossini PM (2011) Ceruloplasmin/Transferrin ratio changes in Alzheimer's disease. Int J Alzheimers Dis 2011, 231595.
44. Hoogenraad TU (2011) Paradigm shift in treatment of Alzheimer's disease: Zinc therapy now aconscientious choice for care of individual patients. Int J Alzheimers Dis 2011, 492686.
45. Squitti Ventriglia M, Barbati G, Cassetta E, Ferreri F, Dal Forno G, Ramires S, Zappasodi F, Rossini PM (2007) 'Free' copper in serum of Alzheimer's disease patients correlates with markers of liver function. J Neural Transm 114, 1589-1594. (Pubitemid 350212005)
46. Bucossi S, Mariani S, Ventriglia M, Polimanti R, Gennarelli M, Bonvicini C, Pasqualetti P, Scrascia F, Migliore S, Vernieri F, Rossini PM, Squitti R (2011) Association between the c. 2495 A>G ATP7B Polymorphism and Sporadic Alzheimer's Disease. Int J Alzheimers Dis 2011, 973692.
47. Hoogenraad TU (1996) Monography: Wilson's disease. In: Major Problems in Neurology, 30. W.B Saunders, London.
48. 63rd Annual Meeting of the American Academy of Neurology(2011) Clinical trial results of the first controlled clinical trial of zinc-based therapy for Alzheimer's disease and mild cognitive impairment. Honolulu, Hawaii. 2011.